| Literature DB >> 27148971 |
Jonathan Yap1, Ai Zhen Jin2, Shwe Zin Nyunt3, Tze Pin Ng3, A Mark Richards4,5,6, Carolyn S P Lam1,3,4,7.
Abstract
INTRODUCTION: The prognostic impact of QT interval prolongation has not been well studied in healthy Asians. We investigated the association between the QT interval with mortality and cardiovascular events in a healthy Southeast Asian population.Entities:
Mesh:
Year: 2016 PMID: 27148971 PMCID: PMC4858262 DOI: 10.1371/journal.pone.0154901
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics.
| All (n = 2536) | Women (n = 1711) | Men (n = 825) | P value | |
|---|---|---|---|---|
| Age (SD) | 65.7 (7.5) | 65.2 (7.3) | 66.7 (7.8) | <0.0001 |
| BMI (SD) | 23.7 (3.7) | 23.9, (3.9) | 23.5 (3.3) | 0.010 |
| Ethnicity | ||||
| Chinese (%) | 2337 (92.1%) | 1582 (92.5%) | 755 (91.5%) | 0.1420 |
| Malay (%) | 120 (4.7%) | 81 (4.7%) | 39 (4.7%) | |
| Indian (%) | 60 (2.4%) | 33 (1.9%) | 27 (3.3%) | |
| Others (%) | 19 (0.8%) | 15 (0.9%) | 4 (0.5%) | |
| Diabetes mellitus (%) | 338 (13.3%) | 219 (12.8%) | 119 (14.4%) | 0.2594 |
| Hypertension (%) | 1030 (40.6%) | 699 (40.8%) | 331 (40.1%) | 0.7251 |
| Smoker (%) | 214 (8.4%) | 41 (2.4%) | 173 (21.0%) | <0.0001 |
| Cholesterol (SD) (mmol/L) | 5.5 (0.9) | 5.6 (0.9) | 5.3 (0.9) | <0.0001 |
| Hemoglobin (SD) (g/dl) | 13.4 (1.3) | 13.0 (1.1) | 14.4 (1.4) | <0.0001 |
| Creatinine (SD) (umol/L) | 77.5 (36.5) | 69.6 (31.6) | 94.3 (40.3) | <0.0001 |
| HR (SD) (beats per min) | 69 (11) | 69 (10) | 68 (11) | 0.022 |
| QRS (SD) (ms) | 86 (10) | 84 (10) | 88 (10) | <0.0001 |
| Mean QTcB (SD) (ms) | 442 (50) | 447 (50) | 430 (48) | <0.0001 |
| Median QTcB (IQR) (ms) | 441 (409–474) | 447 (416–479) | 426 (397–462) | |
| Mean QTcF (SD) (ms) | 406 (26) | 410 (27) | 399 (21) | <0.0001 |
| Median QTcF (IQR) (ms) | 406 (393–419) | 410 (397–422) | 397 (386–410) | |
| ACE/ARB (%) | 261 (10.3%) | 169 (9.9%) | 92 (11.2%) | 0.3225 |
| Betablocker (%) | 500 (19.7%) | 347 (20.3%) | 153 (18.6%) | 0.3035 |
| Calcium channel blockers (%) | 94 (3.7%) | 67 (3.9%) | 27 (3.3%) | 0.4219 |
Sex-stratified association of QTcB (categorical) with overall and cardiovascular mortality.
| Unadjusted HR (95% CI) | |||||
|---|---|---|---|---|---|
| QTcB Percentiles | Range | All-cause mortality | Cardiovascular mortality/MI/Stroke | Cardiovascular mortality | MI/Stroke |
| 0–25% | ≤409 | 1.00 | 1.00 | 1.000 | 1.000 |
| 25–50% | 410–440 | 1.14 (0.74–1.75) | 0.84 (0.50–1.41) | 1.145 (0.486–2.697) | 0.765 (0.429–1.364) |
| 50–75% | 441–473 | 1.24 (0.81–1.89) | 1.16 (0.72–1.87) | 0.959 (0.390–2.361) | 1.293 (0.777–2.150) |
| 75–100% | ≥474 | 1.96 (1.33–2.89) | 1.64 (1.05–2.57) | 1.695 (0.761–3.775) | 1.570 (0.958–2.572) |
| Ptrend | 0.0005 | 0.0124 | 0.2478 | 0.0209 | |
| 0–25% | ≤397 | 1.000 | 1.000 | 1.000 | 1.000 |
| 25–50% | 398–425 | 1.52 (0.77–3.01) | 1.24 (0.59–2.60) | 1.761 (0.421–7.369) | 1.173 (0.517–2.660) |
| 50–75% | 426–461 | 1.90 (0.98–3.67) | 1.36 (0.65–2.83) | 1.118 (0.226–5.540) | 1.515 (0.696–3.301) |
| 75–100% | ≥462 | 2.483 (1.321–4.669) | 2.07 (1.04–4.09) | 1.912 (0.457–7.999) | 2.033 (0.965–4.283) |
| Ptrend | 0.0030 | 0.0334 | 0.5129 | 0.0439 | |
| 0–25% | ≤416 | 1.000 | 1.000 | 1.000 | 1.000 |
| 25–50% | 417–446 | 0.790 (0.435–1.435) | 0.97 (0.45–2.1) | 0.738 (0.234–2.327) | 1.038 (0.450–2.394) |
| 50–75% | 447–478 | 1.127 (0.654–1.941) | 1.58 (0.80–3.11) | 0.905 (0.304–2.693) | 1.812 (0.862–3.808) |
| 75–100% | ≥479 | 1.885 (1.149–3.094) | 2.01 (1.04–3.86) | 1.792 (0.694–4.627) | 2.031 (0.973–4.239) |
| Ptrend | 0.0040 | 0.0134 | 0.1857 | 0.0224 | |
Fig 1Kaplan Meier survival curves for mortality by QTcB interval.
Fig 2Kaplan Meier survival curves for major adverse cardiovascular outcomes by QTcB interval.
Association of QTc B (continuous) with overall and cardiovascular mortality.
| Unadjusted | Model 1 | Model 2 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HR (per 10ms) | HR (per 1 SD) | P value | HR (per 10ms) | HR (per 1 SD) | P value | HR (per 10ms) | HR (per 1 SD) | P value | |
| Overall mortality | 1.052 (1.023–1.083) | 1.29 (1.12–1.49) | 0.0004 | 1.052 (1.022–1.083) | 1.27 (1.10–1.47) | 0.0012 | 1.053 (1.022–1.085) | 1.28 (1.10–1.48) | 0.0015 |
| Cardiovascular mortality/MI/Stroke | 1.042 (1.007–1.078) | 1.23 (1.04–1.46) | 0.0185 | 1.047 (1.011–1.085) | 1.22 (1.02–1.445) | 0.0282 | 1.045 (1.009–1.083) | 1.20 (1.01–1.43) | 0.0415 |
| Cardiovascular mortality | 1.028 (0.967–1.092) | 1.15 (0.85–1.55) | 0.3724 | 1.011 (0.949–1.076) | 1.02 (0.74–1.39) | 0.9177 | 1.020 (0.957–1.086) | 1.05 (0.77–1.44) | 0.7562 |
| MI/Stroke | 1.042 (1.004–1.082) | 1.23 (1.02–1.48) | 0.0281 | 1.050 (1.011–1.091) | 1.24 (1.02–1.50) | 0.0281 | 1.046 (1.007–1.087) | 1.22 (1.01–1.47) | 0.0455 |
*adjusted for age, sex, ethnicity
**adjusted for age, sex, ethnicity, BMI, diabetes, hypertension, cholesterol